Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here.
Repligen Corp (RGEN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sivik Global Healthcare Krishen Sud | 20,000 | $3,844,600 | 2.2% | |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 5,503 | $1,057,842 | 0.01% | |
| 3. | 0 | $0 | 0% | ||
| 4. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $112.13 | 1,800 | $201,830.40 | 1,800 | 2025-08-08 | Filing | |
| $150.69 | 250 | $37,672.50 | 1,043 | 2025-03-17 | Filing | |
| $125.46 | 700 | $87,822.00 | 4,613 | 2024-06-14 | Filing | |
| $124.54 | 915 | $113,954.10 | 3,913 | 2024-06-14 | Filing | |
| $125.45 | 1,200 | $150,540.00 | 4,668 | 2024-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $190.00 | 4,202 | $798,380.00 | 45,788 | 2026-10-05 | Filing | |
| $178.75 | 1,333 | $238,273.75 | 45,788 | 2026-10-05 | Filing | |
| $190.00 | 4,542 | $862,980.00 | 48,369 | 2026-09-24 | Filing | |
| $190.00 | 8,404 | $1,596,760.00 | 48,369 | 2026-09-24 | Filing | |
| $180.00 | 5,426 | $976,680.00 | 48,369 | 2026-09-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,086,970 | $208,948,290 | 0.03% | |
| 2. | 1,020,907 | $196,248,953 | 1.27% | |
| 3. | 938,169 | $180,353,858 | 0.03% | |
| 4. | 907,159 | $174,383,175 | 1.29% | |
| 5. | 700,626 | $134,681,336 | 4.07% |
News See All
Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings
Wasatch Global Investors, an asset management company, released its “Small Cap Growth Strategy” Q3 2026 investor letter. The letter can be downloaded here.
New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector
How hot are biotech stocks? One of the bellwethers for the industry, the iShares Biotechnology ETF ($IBB) (left chart), has gained over 24% year to...
Leaving Estimates in the Dust: 28 Firms Beating Earnings Expectations
Research from Morgan Stanley showed that the median EPS surprise for S&P 500 companies reached 6% in the first quarter of 2026, the strongest reading in four years and above the long-run average of around...
Is Repligen Corporation (RGEN) A Good Stock To Buy Now?
Is RGEN a good stock to buy? We came across a bullish thesis on Repligen Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on RGEN.
Here's Why Repligen Corp. (RGEN) Fell 28% in Q1
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first-quarter 2026 investor letter.
Repligen Corporation (RGEN) Dropped Following the Earnings Release
Brown Capital Management, an investment management company, released its first quarter 2026 investor letter for “The Brown Capital Management Small Company Fund”.
Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools
Osterweis Capital Management, an investment management firm, released its Q1 2026 investor update for its “Osterweis Opportunity Fund”. A copy of the letter can be downloaded here.
Billionaire Lee Ainslie's 10 Stocks with Huge Upside Potential
In this article, we will discuss Billionaire Lee Ainslie's 10 Stocks with Huge Upside Potential.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
In this article, we will discuss: 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.
Hedge Fund Resource Center